The Mechanistic Role of Different Mediators in the Pathophysiology of
Nephropathy: A Review

Jaspreet      Singh; Akash      Jain; Rashmi      Bhamra; Vaibhav      Rathi; Ashwani   K.   Dhingra
doi:10.2174/1389450124666221026152647
Abstract

Nephropathy has become the most common reason for end-stage renal disease worldwide. The progression of end-stage renal disease occurs caused by decreased glomerular filtration rate, damage to capillaries in renal glomeruli or a higher risk of cardiovascular morbidity and mortality in diabetic patients. The involvement of mechanism in the development of nephropathy via generation of AGEs, the elevation of growth factors, altered hemodynamic and metabolic factors, inflammatory mediators, oxidative stress and dyslipidaemia. The prevalence of chronic kidney disease in India will rise from 3.7 million in 1990 to 7.63 million in 2020 becoming the main cause of mortality and morbidity. The pathogenesis of nephropathy mediates by various molecules that cause alterations in the structure and function of the kidney like growth factors, endothelins, transforming growth factor (TGF-β), and Angiotensin-converting enzymes (ACE), fibronectin and proinflammatory cytokines, mast cells and dyslipidemia. Growth factors like VEGF, IGFs, PDGF, EGFR and TGF-β contribute to excessive extracellular matrix accumulation, together with thickening of the glomerular and tubular basement membranes and an increase in the mesangial matrix, leading to glomerulosclerosis and tubulointerstitial fibrosis. Oxidative stress and inflammation factors like TNF-α, IL-1 and IL-6 are hypothesized to play a role in the development of pathological changes in nephropathy like renal hyperfiltration and hypertrophy, thickening of the glomerular basement membrane (GBM), glomerular lesion and tubulointerstitial fibrosis. Dyslipidemia is involved in the progression of nephropathy by impaired action of lipoprotein lipase, lecithincholesterol acyltransferase (LCAT) and cholesteryl ester transferase protein (CETP) resulting in the increased level of LDL-C, Triglyceride level and decrease HDL-C that enhance macrophage infiltration, excessive extracellular matrix production and accelerate inflammation with the development of proteinuria. Interruption in the RAS, oxidative stress and dyslipidemia have yielded much better results in terms of reno-protection and progression of nephropathy. In this review, we would focus on various factors that have been shown to contribute to renal injury in many experimental models of nephropathy.
« Previous Next »
Graphical Abstract

[1]
Lim A. Diabetic nephropathy-complications and treatment. Int J Nephrol Renovasc Dis  2014; 7: 361-81.
 [http://dx.doi.org/10.2147/IJNRD.S40172] [PMID: 25342915]

[2]
Reidy K, Kang HM, Hostetter T, Susztak K. Molecular mechanisms of diabetic kidney disease. J Clin Invest  2014; 124(6): 2333-40.
 [http://dx.doi.org/10.1172/JCI72271] [PMID: 24892707]

[3]
Gall MA, Rossing P, Skøtt P, et al. Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin-dependent) diabetic patients. Diabetologia  1991; 34(9): 655-61.
 [http://dx.doi.org/10.1007/BF00400995] [PMID: 1955098]

[4]
Tunstall-Pedoe H. Preventing Chronic Diseases A vital investment: WHO Global Report.  Geneva: World Health Organization 2005; p. 200.

[5]
Fioretto P, Mauer M, Brocco E, et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia  1996; 39(12): 1569-76.
 [http://dx.doi.org/10.1007/s001250050616] [PMID: 8960844]

[6]
Wolf G. Growth factors and the development of diabetic nephropathy. Curr Diab Rep  2003; 3(6): 485-90.
 [http://dx.doi.org/10.1007/s11892-003-0012-2] [PMID: 14611745]

[7]
Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature  2001; 414(6865): 813-20.
 [http://dx.doi.org/10.1038/414813a] [PMID: 11742414]

[8]
Sun GD, Li CY, Cui WP, et al. Review of herbal traditional chinese medicine for the treatment of diabetic nephropathy. J Diabetes Res 2016; 2016.

[9]
Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol  2008; 19(3): 433-42.
 [http://dx.doi.org/10.1681/ASN.2007091048] [PMID: 18256353]

[10]
Cao Z, Cooper ME. Pathogenesis of diabetic nephropathy. J Diabetes Investig  2011; 2(4): 243-7.
 [http://dx.doi.org/10.1111/j.2040-1124.2011.00131.x] [PMID: 24843491]

[11]
Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet  1998; 352(9123): 213-9.
 [http://dx.doi.org/10.1016/S0140-6736(98)01346-4] [PMID: 9683226]

[12]
Li YC, Shih YM, Lee JA. Gentamicin caused renal injury deeply related to methylglyoxal and Nɛ-(carboxyethyl)lysine (CEL). Toxicol Lett  2013; 219(1): 85-92.
 [http://dx.doi.org/10.1016/j.toxlet.2013.01.024] [PMID: 23454834]

[13]
Maxey L, Magnusson J. Rehabilitation for the Postsurgical Orthopedic Patient. Amsterdam: Elsevier Health Sciences 2013.

[14]
Stone WL, Varacallo M. Physiology, growth factor.Stat Pearls. Treasure Island, FL: Stat Pearls Publishing  2022. Internet

[15]
Chiarelli F, Gaspari S, Marcovecchio ML. Role of growth factors in diabetic kidney disease. Horm Metab Res  2009; 41(8): 585-93.
 [http://dx.doi.org/10.1055/s-0029-1220752] [PMID: 19452424]

[16]
Ferrara N, Gerber HP. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol  2001; 106(4): 148-56.
 [http://dx.doi.org/10.1159/000046610] [PMID: 11815711]

[17]
Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J  1999; 13(1): 9-22.
 [http://dx.doi.org/10.1096/fasebj.13.1.9] [PMID: 9872925]

[18]
Guan F, Villegas G, Teichman J, Mundel P, Tufro A. Autocrine VEGF-A system in podocytes regulates podocin and its interaction with CD2AP. Am J Physiol Renal Physiol  2006; 291(2): F422-8.
 [http://dx.doi.org/10.1152/ajprenal.00448.2005] [PMID: 16597608]

[19]
Sison K, Eremina V, Baelde H, et al. Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J Am Soc Nephrol  2010; 21(10): 1691-701.
 [http://dx.doi.org/10.1681/ASN.2010030295] [PMID: 20688931]

[20]
Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol  1998; 274(3): H1054-8.
 [PMID: 9530221]

[21]
Mount PF, Power DA. Nitric oxide in the kidney: Functions and regulation of synthesis. Acta Physiol  2006; 187(4): 433-46.
 [http://dx.doi.org/10.1111/j.1748-1716.2006.01582.x] [PMID: 16866775]

[22]
Zoccali C. The endothelium as a target in renal diseases. J Nephrol  2007; 20(S12): S39-44.
 [PMID: 18050141]

[23]
Sivaskandarajah GA, Jeansson M, Maezawa Y, Eremina V, Baelde HJ, Quaggin SE. Vegfa protects the glomerular microvasculature in diabetes. Diabetes  2012; 61(11): 2958-66.
 [http://dx.doi.org/10.2337/DB11-1655] [PMID: 23093658]

[24]
Iida H, Seifert R, Alpers CE, et al. Platelet-derived growth factor (PDGF) and PDGF receptor are induced in mesangial proliferative nephritis in the rat. Proc Natl Acad Sci  1991; 88(15): 6560-4.
 [http://dx.doi.org/10.1073/pnas.88.15.6560] [PMID: 1713682]

[25]
Ostendorf T, Eitner F, Floege J. The PDGF family in renal fibrosis. Pediatr Nephrol  2012; 27(7): 1041-50.
 [http://dx.doi.org/10.1007/s00467-011-1892-z] [PMID: 21597969]

[26]
Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev  2008; 22(10): 1276-312.
 [http://dx.doi.org/10.1101/gad.1653708] [PMID: 18483217]

[27]
Floege J, Eng E, Young BA, et al. Infusion of platelet-derived growth factor or basic fibroblast growth factor induces selective glomerular mesangial cell proliferation and matrix accumulation in rats. J Clin Invest  1993; 92(6): 2952-62.
 [http://dx.doi.org/10.1172/JCI116918] [PMID: 7902849]

[28]
Schöcklmann HO, Lang S, Sterzel RB. Regulation of mesangial cell proliferation. Kidney Int  1999; 56(4): 1199-207.
 [http://dx.doi.org/10.1046/j.1523-1755.1999.00710.x] [PMID: 10610410]

[29]
Johnson RJ, Raines EW, Floege J, et al. Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor. J Exp Med  1992; 175(5): 1413-6.
 [http://dx.doi.org/10.1084/jem.175.5.1413] [PMID: 1569407]

[30]
Dennler S, Goumans MJ, ten Dijke P. Transforming growth factor β signal transduction. J Leukoc Biol  2002; 71(5): 731-40.
 [http://dx.doi.org/10.1189/jlb.71.5.731] [PMID: 11994497]

[31]
Patel SR, Dressler GR. BMP7 signaling in renal development and disease. Trends Mol Med  2005; 11(11): 512-8.
 [http://dx.doi.org/10.1016/j.molmed.2005.09.007] [PMID: 16216558]

[32]
Wrana JL, Attisano L, Wieser R, Ventura F, Massagué J. Mechanism of activation of the TGF-β receptor. Nature  1994; 370(6488): 341-7.
 [http://dx.doi.org/10.1038/370341a0] [PMID: 8047140]

[33]
Chang AS, Hathaway CK, Smithies O, Kakoki M. Transforming growth factor-β1 and diabetic nephropathy. Am J Physiol Renal Physiol  2016; 310(8): F689-96.
 [http://dx.doi.org/10.1152/ajprenal.00502.2015] [PMID: 26719364]

[34]
Lan HY. Diverse roles of TGF-β/Smads in renal fibrosis and inflammation. Int J Biol Sci  2011; 7(7): 1056-67.
 [http://dx.doi.org/10.7150/ijbs.7.1056] [PMID: 21927575]

[35]
Mason RM. Connective tissue growth factor(CCN2), a pathogenic factor in diabetic nephropathy. What does it do? How does it do it? J Cell Commun Signal  2009; 3(2): 95-104.
 [http://dx.doi.org/10.1007/s12079-009-0038-6] [PMID: 19214781]

[36]
Burns WC, Twigg SM, Forbes JM, et al. Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: Implications for diabetic renal disease. J Am Soc Nephrol  2006; 17(9): 2484-94.
 [http://dx.doi.org/10.1681/ASN.2006050525] [PMID: 16914537]

[37]
Leask A, Abraham DJ. All in the CCN family: Essential matricellular signaling modulators emerge from the bunker. J Cell Sci  2006; 119(23): 4803-10.
 [http://dx.doi.org/10.1242/jcs.03270] [PMID: 17130294]

[38]
Wahab NA, Weston BS, Mason RM. Connective tissue growth factor CCN2 interacts with and activates the tyrosine kinase receptor TrkA. J Am Soc Nephrol  2005; 16(2): 340-51.
 [http://dx.doi.org/10.1681/ASN.2003100905] [PMID: 15601748]

[39]
Patel SR, Dressler GR. Outstanding questions. Trends Mol Med  2005; 11(11): 512-8.
 [http://dx.doi.org/10.1016/j.molmed.2005.09.007] [PMID: 16216558]

[40]
Wang S, de Caestecker M, Kopp J, Mitu G, LaPage J, Hirschberg R. Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J Am Soc Nephrol  2006; 17(9): 2504-12.
 [http://dx.doi.org/10.1681/ASN.2006030278] [PMID: 16899516]

[41]
Bach LA, Hale LJ. Insulin-like growth factors and kidney disease. Am J Kidney Dis  2015; 65(2): 327-36.
 [http://dx.doi.org/10.1053/j.ajkd.2014.05.024] [PMID: 25151409]

[42]
Dupont J, LeRoith D. Insulin and insulin-like growth factor I receptors: Similarities and differences in signal transduction. Horm Res  2001; 55(S2): 22-6.
 [PMID: 11684871]

[43]
Vasylyeva TL, Ferry RJ Jr. Novel roles of the IGF-IGFBP axis in etiopathophysiology of diabetic nephropathy. Diabetes Res Clin Pract  2007; 76(2): 177-86.
 [http://dx.doi.org/10.1016/j.diabres.2006.09.012] [PMID: 17011663]

[44]
Whaley-Connell A, Sowers JR. Insulin resistance in kidney disease: Is there a distinct role separate from that of diabetes or obesity. Cardiorenal Med  2018; 8(1): 41-9.
 [http://dx.doi.org/10.1159/000479801] [PMID: 29344025]

[45]
Holbro T, Hynes NE. ErbB receptors: Directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol  2004; 44(1): 195-217.
 [http://dx.doi.org/10.1146/annurev.pharmtox.44.101802.121440] [PMID: 14744244]

[46]
Bollée G, Flamant M, Schordan S, et al. Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis. Nat Med  2011; 17(10): 1242-50.
 [http://dx.doi.org/10.1038/nm.2491] [PMID: 21946538]

[47]
Melenhorst WBWH, Mulder GM, Xi Q, et al. Epidermal growth factor receptor signaling in the kidney: Key roles in physiology and disease. Hypertension  2008; 52(6): 987-93.
 [http://dx.doi.org/10.1161/HYPERTENSIONAHA.108.113860] [PMID: 18981331]

[48]
Zeng F, Singh AB, Harris RC. The role of the EGF family of ligands and receptors in renal development, physiology and pathophysiology. Exp Cell Res  2009; 315(4): 602-10.
 [http://dx.doi.org/10.1016/j.yexcr.2008.08.005] [PMID: 18761338]

[49]
Rayego-Mateos S, Rodrigues-Diez R, Morgado-Pascual JL, et al. Role of epidermal growth factor receptor (EGFR) and its ligands in kidney inflammation and damage. Mediators Inflamm  2018; 2018: 1-22.
 [http://dx.doi.org/10.1155/2018/8739473]

[50]
Fischer OM, Hart S, Gschwind A, Ullrich A. EGFR signal transactivation in cancer cells. Biochem Soc Trans  2003; 31(6): 1203-8.
 [http://dx.doi.org/10.1042/bst0311203] [PMID: 14641026]

[51]
Alsaad KO, Herzenberg AM. Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: An update. J Clin Pathol  2007; 60(1): 18-26.
 [http://dx.doi.org/10.1136/jcp.2005.035592] [PMID: 17213346]

[52]
Chen S, Jim B, Ziyadeh FN. Diabetic nephropathy and transforming growth factor-β Transforming our view of glomerulosclerosis and fibrosis build-up. Semin Nephrol  2003; 23(6): 532-43.
 [http://dx.doi.org/10.1053/S0270-9295(03)00132-3] [PMID: 14631561]

[53]
Thrailkill KM, Clay Bunn R, Fowlkes JL. Matrix metalloproteinases: Their potential role in the pathogenesis of diabetic nephropathy. Endocrine  2009; 35(1): 1-10.
 [http://dx.doi.org/10.1007/s12020-008-9114-6] [PMID: 18972226]

[54]
Lan T, Liu W, Xie X, et al. Sphingosine kinase-1 pathway mediates high glucose-induced fibronectin expression in glomerular mesangial cells. Mol Endocrinol  2011; 25(12): 2094-105.
 [http://dx.doi.org/10.1210/me.2011-0095] [PMID: 21998146]

[55]
Qian Y, Feldman E, Pennathur S, Kretzler M, Brosius FC III. From fibrosis to sclerosis: Mechanisms of glomerulosclerosis in diabetic nephropathy. Diabetes  2008; 57(6): 1439-45.
 [http://dx.doi.org/10.2337/db08-0061] [PMID: 18511444]

[56]
García-García PM, Getino-Melián MA, Domínguez-Pimentel V, Navarro-González JF. Inflammation in diabetic kidney disease. World J Diabetes  2014; 5(4): 431-43.
 [http://dx.doi.org/10.4239/wjd.v5.i4.431] [PMID: 25126391]

[57]
Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones: An assessment from bench to bedside. Kidney Int  2006; 70(7): 1223-33.
 [http://dx.doi.org/10.1038/sj.ki.5001620] [PMID: 16883325]

[58]
Hai W, Ping X, Zhi-wen Y, Chun Z. [RETRACTED ARTICLE] Therapeutic effect and potential mechanism of pioglitazone in rats with severe acute pancreatitis. Braz J Med Biol Res  2018; 51(2): e6812.
 [http://dx.doi.org/10.1590/1414-431x20176812] [PMID: 29267505]

[59]
Donate-Correa J, Martín-Núñez E, Muros-de-Fuentes M, Mora-Fernández C, Navarro-González JF. Inflammatory cytokines in diabetic nephropathy. J Diabetes Res  2015; 2015: 1-9.
 [http://dx.doi.org/10.1155/2015/948417] [PMID: 25785280]

[60]
Navarro-González JF, Mora-Fernández C, de Fuentes MM, García-Pérez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol  2011; 7(6): 327-40.
 [http://dx.doi.org/10.1038/nrneph.2011.51] [PMID: 21537349]

[61]
Priante G, Gianesello L, Ceol M, Del Prete D, Anglani F. Cell death in the kidney. Int J Mol Sci  2019; 20(14): 3598.
 [http://dx.doi.org/10.3390/ijms20143598] [PMID: 31340541]

[62]
Berghe TV, Linkermann A, Jouan-Lanhouet S, Walczak H, Vandenabeele P. Regulated necrosis: The expanding network of non-apoptotic cell death pathways. Nat Rev Mol Cell Biol  2014; 15(2): 135-47.
 [http://dx.doi.org/10.1038/nrm3737] [PMID: 24452471]

[63]
Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ  2003; 10(1): 45-65.
 [http://dx.doi.org/10.1038/sj.cdd.4401189] [PMID: 12655295]

[64]
Sindhughosa DA, Pranamartha AG. The involvement of proinflammatory cytokines in diabetic nephropathy: Focus on interleukin 1 (IL-1), interleukin 6 (IL-6), and tumor necrosis factor-alpha (TNF-α) signaling mechanism. BMJ  2017; 6: 299.

[65]
Ozbek E, Cekmen M, Ilbey YO, Simsek A, Polat EC, Somay A. Atorvastatin prevents gentamicin-induced renal damage in rats through the inhibition of p38-MAPK and NF-kappaB pathways. Ren Fail  2009; 31(5): 382-92.
 [http://dx.doi.org/10.1080/08860220902835863] [PMID: 19839839]

[66]
Rao V, Rao LV, Tan SH, Candasamy M, Bhattamisra SK. Diabetic nephropathy: An update on pathogenesis and drug development. Diabetes Metab Syndr  2019; 13(1): 754-62.
 [http://dx.doi.org/10.1016/j.dsx.2018.11.054] [PMID: 30641802]

[67]
Murray KN, Parry-Jones AR, Allan SM. Interleukin-1 and acute brain injury. Front Cell Neurosci  2015; 9: 18.
 [http://dx.doi.org/10.3389/fncel.2015.00018] [PMID: 25705177]

[68]
Satirapoj B. Diabetic kidney disease: Important mechanisms and treatment. J Nephrol Soc Thai  2009; 15(2): 126-39.

[69]
Suzuki D, Miyazaki M, Naka R, et al. In situ hybridization of interleukin 6 in diabetic nephropathy. Diabetes  1995; 44(10): 1233-8.
 [http://dx.doi.org/10.2337/diab.44.10.1233] [PMID: 7556963]

[70]
Nishimoto N, Kishimoto T. Interleukin 6: From bench to bedside. Nat Clin Pract Rheumatol  2006; 2(11): 619-26.
 [http://dx.doi.org/10.1038/ncprheum0338] [PMID: 17075601]

[71]
Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapyThis article is one of a selection of papers published in the special issue (part 2 of 2) on Forefronts in Endothelin. Can J Physiol Pharmacol  2008; 86(8): 485-98.
 [http://dx.doi.org/10.1139/Y08-059] [PMID: 18758495]

[72]
Benz K, Amann K. Endothelin in diabetic renal disease. Contrib Nephrol  2011; 172: 139-48.
 [http://dx.doi.org/10.1159/000328695]

[73]
Rebibou JM, He CJ, Delarue F, et al. Functional endothelin 1 receptors on human glomerular podocytes and mesangial cells. Nephrol Dial Transplant  1992; 7(4): 288-92.
 [http://dx.doi.org/10.1093/oxfordjournals.ndt.a092130] [PMID: 1317517]

[74]
Saleh MA, Boesen EI, Pollock JS, Savin VJ, Pollock DM. Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat. Hypertension  2010; 56(5): 942-9.
 [http://dx.doi.org/10.1161/HYPERTENSIONAHA.110.156570] [PMID: 20823379]

[75]
Nishiyama A, Kobori H. Independent regulation of renin-angiotensin-aldosterone system in the kidney. Clin Exp Nephrol  2018; 22(6): 1231-9.
 [http://dx.doi.org/10.1007/s10157-018-1567-1] [PMID: 29600408]

[76]
Singh R, Singh AK, Alavi N, Leehey DJ. Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose. J Am Soc Nephrol  2003; 14(4): 873-80.
 [http://dx.doi.org/10.1097/01.ASN.0000060804.40201.6E] [PMID: 12660321]

[77]
Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest  1994; 93(6): 2431-7.
 [http://dx.doi.org/10.1172/JCI117251] [PMID: 8200978]

[78]
Edwards RM, Aiyar N. Angiotensin II receptor subtypes in the kidney. J Am Soc Nephrol  1993; 3(10): 1643-52.
 [http://dx.doi.org/10.1681/ASN.V3101643] [PMID: 8318680]

[79]
Sparks MA, Crowley SD, Gurley SB, Mirotsou M, Coffman TM. Classical Renin-Angiotensin system in kidney physiology. Compr Physiol  2014; 4(3): 1201-28.
 [http://dx.doi.org/10.1002/cphy.c130040] [PMID: 24944035]

[80]
Basile D, Yoder M. Renal endothelial dysfunction in acute kidney ischemia reperfusion injury. Cardiovasc Hematol Disord Drug Targets  2014; 14(1): 3-14.
 [http://dx.doi.org/10.2174/1871529X1401140724093505] [PMID: 25088124]

[81]
Hodgkins KS, Schnaper HW. Tubulointerstitial injury and the progression of chronic kidney disease. Pediatr Nephrol  2012; 27(6): 901-9.
 [http://dx.doi.org/10.1007/s00467-011-1992-9] [PMID: 21947270]

[82]
Ruilope LM. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers? Acta Diabetol  2005; 42(S1): s33-41.
 [http://dx.doi.org/10.1007/s00592-005-0179-x] [PMID: 15868118]

[83]
Bauer JH, Reams GP. Renal protection in essential hypertension: How do angiotensin-converting enzyme inhibitors compare with calcium antagonists? J Am Soc Nephrol  1990; 1(5)(S2): S80-7.
 [PMID: 16989071]

[84]
Stumpe KO. Angiotensin-converting enzyme inhibition: Direct and indirect mechanisms. Klin Wochenschr  1985; 63(18): 897-906.
 [http://dx.doi.org/10.1007/BF01738143] [PMID: 2997540]

[85]
Delles C, Jacobi J, John S, Fleischmann I, Schmieder RE. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension. Kidney Int  2002; 61(4): 1462-8.
 [http://dx.doi.org/10.1046/j.1523-1755.2002.00260.x] [PMID: 11918753]

[86]
Francischetti A, Ono H, Frohlich ED. Renoprotective effects of felodipine and/or enalapril in spontaneously hypertensive rats with and without L-NAME. Hypertension  1998; 31(3): 795-801.
 [http://dx.doi.org/10.1161/01.HYP.31.3.795] [PMID: 9495263]

[87]
Wilens SL, Elster SK. The role of lipid deposition in renal arteriolar sclerosis. Am J Med Sci  1950; 219(2): 183-196, illust.
 [http://dx.doi.org/10.1097/00000441-195002000-00009] [PMID: 15403163]

[88]
Groop PH, Elliott T, Friedman R, et al. Multiple lipoprotein abnormalities in type I diabetic patients with renal disease. Diabetes  1996; 45(7): 974-9.
 [http://dx.doi.org/10.2337/diab.45.7.974] [PMID: 8666151]

[89]
Attman P, Knight-Gibson C, Tavella M, Samuelsson O, Alaupovic P. The compositional abnormalities of lipoproteins in diabetic renal failure. Nephrol Dial Transplant  1998; 13(11): 2833-41.
 [http://dx.doi.org/10.1093/ndt/13.11.2833] [PMID: 9829487]

[90]
Hirano T, Naito H, Kurokawa M, et al. High prevalence of small LDL particles in non-insulin-dependent diabetic patients with nephropathy. Atherosclerosis  1996; 123(1-2): 57-72.
 [http://dx.doi.org/10.1016/0021-9150(95)05772-2] [PMID: 8782837]

[91]
Listenberger LL, Han X, Lewis SE, et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci  2003; 100(6): 3077-82.
 [http://dx.doi.org/10.1073/pnas.0630588100] [PMID: 12629214]

[92]
Abrass CK. Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol  2004; 24(1): 46-53.
 [http://dx.doi.org/10.1159/000075925] [PMID: 14707435]

[93]
Chait A, Heinecke JW. Lipoprotein modification. Curr Opin Lipidol  1994; 5(5): 365-70.
 [http://dx.doi.org/10.1097/00041433-199410000-00008] [PMID: 7858911]

[94]
Wheeler DC, Chana RS. Interactions between lipoproteins, glomerular cells and matrix. Miner Electrolyte Metab  1993; 19(3): 149-64.
 [PMID: 8232102]

[95]
Weinberg JM. Lipotoxicity. Kidney Int  2006; 70(9): 1560-6.
 [http://dx.doi.org/10.1038/sj.ki.5001834] [PMID: 16955100]

[96]
Choi ME. Mechanism of transforming growth factor-β1 signaling: Role of the mitogen-activated protein kinase. Kidney Int  2000; 58: S53-8.
 [http://dx.doi.org/10.1046/j.1523-1755.2000.07709.x]

[97]
Prakash J. Dyslipidemia in diabetic kidney disease. Clin Queries Nephrol  2012; 1(2): 115-8.
 [http://dx.doi.org/10.1016/S2211-9477(12)70003-1]

[98]
Kamanna VS, Bassa BV, Ganji SH. Low density lipoproteins transactivate EGF receptor: Role in mesangial cell proliferation. Life Sci  2008; 83(17-18): 595-601.
 [http://dx.doi.org/10.1016/j.lfs.2008.08.010] [PMID: 18805430]

[99]
Lee HS. Oxidized LDL, glomerular mesangial cells and collagen. Diabetes Res Clin Pract  1999; 45(2-3): 117-22.
 [http://dx.doi.org/10.1016/S0168-8227(99)00040-6] [PMID: 10588363]

[100]
Vaziri ND. Dyslipidemia of chronic renal failure: The nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol  2006; 290(2): F262-72.
 [http://dx.doi.org/10.1152/ajprenal.00099.2005] [PMID: 16403839]

[101]
Glass CK, Witztum JL. Atherosclerosis. Cell  2001; 104(4): 503-16.
 [http://dx.doi.org/10.1016/S0092-8674(01)00238-0] [PMID: 11239408]

[102]
Portilla D, Mandel LJ, Bar-Sagi D, Millington DS. Anoxia induces phospholipase A2 activation in rabbit renal proximal tubules. Am J Physiol  1992; 262(3 Pt 2): F354-60.
 [PMID: 1558154]

[103]
Ruan XZ, Moorhead JF, Fernando R, Wheeler DC, Powis SH, Varghese Z. PPAR agonists protect mesangial cells from interleukin 1β-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway. J Am Soc Nephrol  2003; 14(3): 593-600.
 [http://dx.doi.org/10.1097/01.ASN.0000050414.52908.DA] [PMID: 12595494]

[104]
Nishida Y, Oda H, Yorioka N. Effect of lipoproteins on mesangial cell proliferation. Kidney Int  1999; 56: S51-3.
 [http://dx.doi.org/10.1046/j.1523-1755.1999.07113.x] [PMID: 10412737]

[105]
Mayrhofer C, Krieger S, Huttary N, et al. Alterations in fatty acid utilization and an impaired antioxidant defense mechanism are early events in podocyte injury: A proteomic analysis. Am J Pathol  2009; 174(4): 1191-202.
 [http://dx.doi.org/10.2353/ajpath.2009.080654] [PMID: 19264907]

[106]
Su Y, Chen Q, Ma K, et al. Astragaloside IV inhibits palmitate-mediated oxidative stress and fibrosis in human glomerular mesangial cells via downregulation of CD36 expression. Pharmacol Rep  2019; 71(2): 319-29.
 [http://dx.doi.org/10.1016/j.pharep.2018.12.008] [PMID: 30826573]

[107]
Nosadini R, Tonolo G. Role of oxidized low density lipoproteins and free fatty acids in the pathogenesis of glomerulopathy and tubulointerstitial lesions in type 2 diabetes. Nutr Metab Cardiovasc Dis  2011; 21(2): 79-85.
 [http://dx.doi.org/10.1016/j.numecd.2010.10.002] [PMID: 21186102]

[108]
Couser WG. Primary membranous nephropathy. Clin J Am Soc Nephrol  2017; 12(6): 983-97.
 [http://dx.doi.org/10.2215/CJN.11761116] [PMID: 28550082]

[109]
Eom M, Hudkins KL, Alpers CE. Foam cells and the pathogenesis of kidney disease. Curr Opin Nephrol Hypertens  2015; 24(3): 1.
 [http://dx.doi.org/10.1097/MNH.0000000000000112] [PMID: 25887903]

[110]
Takemura T, Yoshioka K, Aya N, et al. Apolipoproteins and lipoprotein receptors in glomeruli in human kidney diseases. Kidney Int  1993; 43(4): 918-27.
 [http://dx.doi.org/10.1038/ki.1993.129] [PMID: 8479130]

[111]
Jiang T, Liebman SE, Scott Lucia M, Li J, Levi M. Role of altered renal lipid metabolism and the sterol regulatory element binding proteins in the pathogenesis of age-related renal disease. Kidney Int  2005; 68(6): 2608-20.
 [http://dx.doi.org/10.1111/j.1523-1755.2005.00733.x] [PMID: 16316337]

[112]
Hara S, Kobayashi N, Sakamoto K, et al. Podocyte injury-driven lipid peroxidation accelerates the infiltration of glomerular foam cells in focal segmental glomerulosclerosis. Am J Pathol  2015; 185(8): 2118-31.
 [http://dx.doi.org/10.1016/j.ajpath.2015.04.007] [PMID: 26072030]

[113]
Wang TN, Chen X, Li R, et al. SREBP-1 mediates angiotensin II-induced TGF-β1 upregulation and glomerular fibrosis. J Am Soc Nephrol  2015; 26(8): 1839-54.
 [http://dx.doi.org/10.1681/ASN.2013121332] [PMID: 25398788]

[114]
Zhou C, Lei H, Chen Y, et al. Enhanced SCAP glycosylation by inflammation induces macrophage foam cell formation. PLoS One  2013; 8(10): e75650.
 [http://dx.doi.org/10.1371/journal.pone.0075650] [PMID: 24146768]

[115]
Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science  2010; 329(5993): 841-5.
 [http://dx.doi.org/10.1126/science.1193032] [PMID: 20647424]

[116]
Hashizume M, Mihara M. Atherogenic effects of TNF-α and IL-6 via up-regulation of scavenger receptors. Cytokine  2012; 58(3): 424-30.
 [http://dx.doi.org/10.1016/j.cyto.2012.02.010] [PMID: 22436638]

[117]
Wang XX, Jiang T, Shen Y, et al. The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria. Am J Physiol Renal Physiol  2009; 297(6): F1587-96.
 [http://dx.doi.org/10.1152/ajprenal.00404.2009] [PMID: 19776172]

[118]
Gai Z, Gui T, Hiller C, Kullak-Ublick GA. Farnesoid X receptor protects against kidney injury in uninephrectomized obese mice. J Biol Chem  2016; 291(5): 2397-411.
 [http://dx.doi.org/10.1074/jbc.M115.694323] [PMID: 26655953]

[119]
Wang X, Collins HL, Ranalletta M, et al. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest  2007; 117(8): 2216-24.
 [http://dx.doi.org/10.1172/JCI32057] [PMID: 17657311]

[120]
Tang C, Kanter JE, Bornfeldt KE, Leboeuf RC, Oram JF. Diabetes reduces the cholesterol exporter ABCA1 in mouse macrophages and kidneys. J Lipid Res  2010; 51(7): 1719-28.
 [http://dx.doi.org/10.1194/jlr.M003525] [PMID: 19965614]

[121]
Ducasa GM, Mitrofanova A, Mallela SK, et al. ATP-binding cassette A1 deficiency causes cardiolipin-driven mitochondrial dysfunction in podocytes. J Clin Invest  2019; 129(8): 3387-400.
 [http://dx.doi.org/10.1172/JCI125316] [PMID: 31329164]

[122]
Yin Q, Zhang R, Li L, et al. Exendin-4 ameliorates lipotoxicity-induced glomerular endothelial cell injury by improving ABC transporter A1-mediated cholesterol efflux in diabetic apoE knockout mice. J Biol Chem  2016; 291(51): 26487-501.
 [http://dx.doi.org/10.1074/jbc.M116.730564] [PMID: 27784780]

[123]
Yvan-Charvet L, Wang N, Tall AR. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb Vasc Biol  2010; 30(2): 139-43.
 [http://dx.doi.org/10.1161/ATVBAHA.108.179283] [PMID: 19797709]

[124]
Yuhanna IS, Zhu Y, Cox BE, et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med  2001; 7(7): 853-7.
 [http://dx.doi.org/10.1038/89986] [PMID: 11433352]

[125]
Vaziri ND, Norris K. Lipid disorders and their relevance to outcomes in chronic kidney disease. Blood Purif  2011; 31(1-3): 189-96.
 [http://dx.doi.org/10.1159/000321845] [PMID: 21228589]

[126]
Di Bartolo B, Scherer DJ, Brown A, Psaltis PJ, Nicholls SJ. PCSK9 inhibitors in hyperlipidemia: Current status and clinical outlook. BioDrugs  2017; 31(3): 167-74.
 [http://dx.doi.org/10.1007/s40259-017-0220-y] [PMID: 28424973]

[127]
Macé C, Chugh SS. Nephrotic syndrome: Components, connections, and angiopoietin-like 4-related therapeutics. J Am Soc Nephrol  2014; 25(11): 2393-8.
 [http://dx.doi.org/10.1681/ASN.2014030267] [PMID: 24854282]

[128]
Sukonina V, Lookene A, Olivecrona T, Olivecrona G. Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue. Proc Natl Acad Sci  2006; 103(46): 17450-5.
 [http://dx.doi.org/10.1073/pnas.0604026103] [PMID: 17088546]

[129]
Hagberg CE, Mehlem A, Falkevall A, et al. Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes. Nature  2012; 490(7420): 426-30.
 [http://dx.doi.org/10.1038/nature11464] [PMID: 23023133]

[130]
Fessler MB, Parks JS. Intracellular lipid flux and membrane microdomains as organizing principles in inflammatory cell signaling. J Immunol  2011; 187(4): 1529-35.
 [http://dx.doi.org/10.4049/jimmunol.1100253] [PMID: 21810617]

[131]
Pommer W. Preventive nephrology: the role of obesity in different stages of chronic kidney disease. Kidney Dis  2018; 4(4): 199-204.
 [http://dx.doi.org/10.1159/000490247] [PMID: 30574496]

[132]
Kasiske BL, O’donnell MP, Cleary MP, Keane WF. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int  1988; 33(3): 667-72.
 [http://dx.doi.org/10.1038/ki.1988.51] [PMID: 3367557]

[133]
Allison SJ. Free fatty acid-induced macropinocytosis in podocytes. Nat Rev Nephrol  2015; 11(7): 386.
 [http://dx.doi.org/10.1038/nrneph.2015.76] [PMID: 25963589]

[134]
Chung JJ, Huber TB, Gödel M, et al. Albumin-associated free fatty acids induce macropinocytosis in podocytes. J Clin Invest  2015; 125(6): 2307-16.
 [http://dx.doi.org/10.1172/JCI79641] [PMID: 25915582]

[135]
Iwai T, Kume S, Chin-Kanasaki M, et al. Stearoyl-CoA desaturase-1 protects cells against lipotoxicity-mediated apoptosis in proximal tubular cells. Int J Mol Sci  2016; 17(11): 1868.
 [http://dx.doi.org/10.3390/ijms17111868] [PMID: 27834856]

[136]
Sieber J, Weins A, Kampe K, et al. Susceptibility of podocytes to palmitic acid is regulated by stearoyl-CoA desaturases 1 and 2. Am J Pathol  2013; 183(3): 735-44.
 [http://dx.doi.org/10.1016/j.ajpath.2013.05.023] [PMID: 23867797]

[137]
Wang Q, Liu S, Zhai A, Zhang B, Tian G. AMPK-mediated regulation of lipid metabolism by phosphorylation. Biol Pharm Bull  2018; 41(7): 985-93.
 [http://dx.doi.org/10.1248/bpb.b17-00724] [PMID: 29709897]

[138]
Guo K, Lu J, Huang Y, et al. Protective role of PGC-1α in diabetic nephropathy is associated with the inhibition of ROS through mitochondrial dynamic remodeling. PLoS One  2015; 10(4): e0125176.
 [http://dx.doi.org/10.1371/journal.pone.0125176] [PMID: 25853493]

[139]
Wei PZ, Szeto CC. Mitochondrial dysfunction in diabetic kidney disease. Clin Chim Acta  2019; 496: 108-16.
 [http://dx.doi.org/10.1016/j.cca.2019.07.005] [PMID: 31276635]

[140]
Liu S, Soong Y, Seshan SV, Szeto HH. Novel cardiolipin therapeutic protects endothelial mitochondria during renal ischemia and mitigates microvascular rarefaction, inflammation, and fibrosis. Am J Physiol Renal Physiol  2014; 306(9): F970-80.
 [http://dx.doi.org/10.1152/ajprenal.00697.2013] [PMID: 24553434]

[141]
Jang HS, Noh MR, Kim J, Padanilam BJ. Defective mitochondrial fatty acid oxidation and lipotoxicity in kidney diseases. Front Med  2020; 7: 65.
 [http://dx.doi.org/10.3389/fmed.2020.00065] [PMID: 32226789]

[142]
Attman PO, Samuelsson O. Dyslipidemia of kidney disease. Curr Opin Lipidol  2009; 20(4): 293-9.
 [http://dx.doi.org/10.1097/MOL.0b013e32832dd832] [PMID: 19512921]

[143]
Fornoni A, Sageshima J, Wei C, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med  2011; 3(85): 85ra46.
 [http://dx.doi.org/10.1126/scitranslmed.3002231] [PMID: 21632984]

[144]
Merscher S, Fornoni A. Podocyte pathology and nephropathy - sphingolipids in glomerular diseases. Front Endocrinol  2014; 5: 127.
 [http://dx.doi.org/10.3389/fendo.2014.00127] [PMID: 25126087]

[145]
Mitrofanova A, Mallela SK, Ducasa GM, et al. SMPDL3b modulates insulin receptor signaling in diabetic kidney disease. Nat Commun  2019; 10(1): 2692.
 [http://dx.doi.org/10.1038/s41467-019-10584-4] [PMID: 31217420]

[146]
Yoo TH, Pedigo CE, Guzman J, et al. Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease. J Am Soc Nephrol  2015; 26(1): 133-47.
 [http://dx.doi.org/10.1681/ASN.2013111213] [PMID: 24925721]

[147]
Fornoni A, Merscher S, Kopp JB. Lipid biology of the podocyte—new perspectives offer new opportunities. Nat Rev Nephrol  2014; 10(7): 379-88.
 [http://dx.doi.org/10.1038/nrneph.2014.87] [PMID: 24861084]

[148]
Li X, Zhang T, Geng J, et al. Advanced oxidation protein products promote lipotoxicity and tubulointerstitial fibrosis via CD36/β-catenin pathway in diabetic nephropathy. Antioxid Redox Signal  2019; 31(7): 521-38.
 [http://dx.doi.org/10.1089/ars.2018.7634] [PMID: 31084358]

[149]
Yang J, Zhang D, Li J, Zhang X, Fan F, Guan Y. Role of PPARγ in renoprotection in Type 2 diabetes: Molecular mechanisms and therapeutic potential. Clin Sci  2009; 116(1): 17-26.
 [http://dx.doi.org/10.1042/CS20070462] [PMID: 19037881]

[150]
Okada-Iwabu M, Yamauchi T, Iwabu M, et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature  2013; 503(7477): 493-9.
 [http://dx.doi.org/10.1038/nature12656] [PMID: 24172895]

[151]
Saxena NK, Anania FA. Adipocytokines and hepatic fibrosis. Trends Endocrinol Metab  2015; 26(3): 153-61.
 [http://dx.doi.org/10.1016/j.tem.2015.01.002] [PMID: 25656826]

[152]
Wang XX, Levi J, Luo Y, et al. SGLT2 protein expression is increased in human diabetic nephropathy SGLT2 protein inhibition decreases renal lipid accumulation, inflammation, and the development of nephropathy in diabetic mice. J Biol Chem  2017; 292(13): 5335-48.
 [http://dx.doi.org/10.1074/jbc.M117.779520] [PMID: 28196866]

[153]
Hagberg CE, Falkevall A, Wang X, et al. Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature  2010; 464(7290): 917-21.
 [http://dx.doi.org/10.1038/nature08945] [PMID: 20228789]

[154]
Hagberg C, Mehlem A, Falkevall A, Muhl L, Eriksson U. Endothelial fatty acid transport: role of vascular endothelial growth factor B. Physiology  2013; 28(2): 125-34.
 [http://dx.doi.org/10.1152/physiol.00042.2012] [PMID: 23455771]

[155]
Schlondorff D. Cellular mechanisms of lipid injury in the glomerulus. Am J Kidney Dis  1993; 22(1): 72-82.
 [http://dx.doi.org/10.1016/S0272-6386(12)70171-3] [PMID: 8322798]

[156]
Guijarro C, Kasiske BL, Kim Y, O’Donnell MP, Keane WF, Keane WF. Early glomerular changes in rats with dietary-induced hypercholesterolemia. Am J Kidney Dis  1995; 26(1): 152-61.
 [http://dx.doi.org/10.1016/0272-6386(95)90169-8] [PMID: 7611247]

[157]
Gröne HJ, Walli AK, Gröne EF. The role of oxidatively modified lipoproteins in lipid nephropathy. Contrib Nephrol  1997; 120: 160-75.
 [http://dx.doi.org/10.1159/000059835] [PMID: 9257059]

[158]
Bank N, Aynedjian HS. Role of thromboxane in impaired renal vasodilatation response to acetylcholine in hypercholesterolemic rats. J Clin Invest  1992; 89(5): 1636-42.
 [http://dx.doi.org/10.1172/JCI115760] [PMID: 1569203]

[159]
Hj G, Hohbach J, Ef G. Modulation of glomerulosclerosis and interstitial fibrosis by native and modified lipoprotein. Kidney Int  1996; 49: S18-22.

[160]
Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int  1997; 51(1): 2-15.
 [http://dx.doi.org/10.1038/ki.1997.2] [PMID: 8995712]

[161]
Sun L, Halaihel N, Zhang W, Rogers T, Levi M. Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J Biol Chem  2002; 277(21): 18919-27.
 [http://dx.doi.org/10.1074/jbc.M110650200] [PMID: 11875060]

[162]
Papaharalambus CA, Griendling KK. Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury. Trends Cardiovasc Med  2007; 17(2): 48-54.
 [http://dx.doi.org/10.1016/j.tcm.2006.11.005] [PMID: 17292046]

[163]
Shahreza FD. Vascular protection by herbal antioxidants; recent views and new concepts. J Prev Epidemiol  2016; 1(1): e05.

[164]
Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes  2008; 57(6): 1446-54.
 [http://dx.doi.org/10.2337/db08-0057] [PMID: 18511445]

[165]
Kashihara N, Haruna Y, Kondeti VK, Kanwar YS. Oxidative stress in diabetic nephropathy. Curr Med Chem  2010; 17(34): 4256-69.
 [http://dx.doi.org/10.2174/092986710793348581] [PMID: 20939814]

[166]
Duni A, Liakopoulos V, Roumeliotis S, Peschos D, Dounousi E. Oxidative stress in the pathogenesis and evolution of chronic kidney disease: Untangling Ariadne’s thread. Int J Mol Sci  2019; 20(15): 3711.
 [http://dx.doi.org/10.3390/ijms20153711] [PMID: 31362427]

[167]
Kerkeni M, Saïdi A, Bouzidi H, Letaief A, Ben Yahia S, Hammami M. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients. Diab Vasc Dis Res  2013; 10(3): 239-45.
 [http://dx.doi.org/10.1177/1479164112460253] [PMID: 23091285]

[168]
Xu GW, Yao QH, Weng QF, Su BL, Zhang X, Xiong JH. Study of urinary 8-hydroxydeoxyguanosine as a biomarker of oxidative DNA damage in diabetic nephropathy patients. J Pharm Biomed Anal  2004; 36(1): 101-4.
 [http://dx.doi.org/10.1016/j.jpba.2004.04.016] [PMID: 15351053]

[169]
Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: A hypothesis. Proc Natl Acad Sci  1981; 78(11): 6858-62.
 [http://dx.doi.org/10.1073/pnas.78.11.6858] [PMID: 6947260]

[170]
Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens  2008; 26(2): 269-75.
 [http://dx.doi.org/10.1097/HJH.0b013e3282f240bf] [PMID: 18192841]

[171]
Wu Y, Wu G, Qi X, et al. Protein kinase C β inhibitor LY333531 attenuates intercellular adhesion molecule-1 and monocyte chemotactic protein-1 expression in the kidney in diabetic rats. J Pharmacol Sci  2006; 101(4): 335-43.
 [http://dx.doi.org/10.1254/jphs.FP0050896] [PMID: 16891764]

[172]
Sun L, Yuan Q, Xu T, et al. Pioglitazone, a peroxisome proliferator-activated receptor γ agonist, ameliorates chronic kidney disease by enhancing antioxidative capacity and attenuating angiogenesis in the kidney of a 5/6 nephrectomized rat model. Cell Physiol Biochem  2016; 38(5): 1831-40.
 [http://dx.doi.org/10.1159/000443121] [PMID: 27160248]

[173]
Fukami K, Yamagishi S, Ueda S, Okuda S. Role of AGEs in diabetic nephropathy. Curr Pharm Des  2008; 14(10): 946-52.
 [http://dx.doi.org/10.2174/138161208784139710] [PMID: 18473844]

[174]
Yamagishi S, Imaizumi T. Diabetic vascular complications: Pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des  2005; 11(18): 2279-99.
 [http://dx.doi.org/10.2174/1381612054367300] [PMID: 16022668]

[175]
Sutariya B, Jhonsa D, Saraf MN. TGF-β the connecting link between nephropathy and fibrosis. Immunopharmacol Immunotoxicol  2016; 38(1): 39-49.
 [http://dx.doi.org/10.3109/08923973.2015.1127382] [PMID: 26849902]

[176]
Lal MA, Brismar H, Eklöf AC, Aperia A. Role of oxidative stress in advanced glycation end product-induced mesangial cell activation. Kidney Int  2002; 61(6): 2006-14.
 [http://dx.doi.org/10.1046/j.1523-1755.2002.00367.x] [PMID: 12028441]

[177]
Machhan N, Joshi JC, Sharma S, Budhiraja RD. Possible role of sodium cromoglycate, a mast cell stabilizer in halting gentamicin nephrotoxicity in rats. Asian J Pharm Res Dev  2017; 5(1): 1-09.

[178]
Pastwińska J, Agier J, Dastych J, Brzezińska-Błaszczyk E. Mast cells as the strength of the inflammatory process. Pol J Pathol  2017; 68(3): 187-96.
 [http://dx.doi.org/10.5114/pjp.2017.71526] [PMID: 29363910]

[179]
Orr S, Bridges C. Chronic kidney disease and exposure to nephrotoxic metals. Int J Mol Sci  2017; 18(5): 1039.
 [http://dx.doi.org/10.3390/ijms18051039] [PMID: 28498320]

[180]
Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol  2010; 21(11): 1819-34.
 [http://dx.doi.org/10.1681/ASN.2010080793] [PMID: 20864689]

[181]
Summers SA, Gan P, Dewage L, et al. Mast cell activation and degranulation promotes renal fibrosis in experimental unilateral ureteric obstruction. Kidney Int  2012; 82(6): 676-85.
 [http://dx.doi.org/10.1038/ki.2012.211] [PMID: 22673890]
Rights & Permissions Print Cite
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1389450124666221026152647	Print ISSN 1389-4501
Publisher Name Bentham Science Publisher	Online ISSN 1873-5592
Current Drug Targets

The Mechanistic Role of Different Mediators in the Pathophysiology of Nephropathy: A Review

Abstract Play Pause

Graphical Abstract

Related Journals

Related Books

Abstract
